Extracellular Vesicle RNAs: New Frontier in IBD Diagnosis and Treatment

A comprehensive review led by researchers at Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, synthesizes the current understanding of extracellular vesicle-associated RNAs (EV-RNAs) and their significant role in inflammatory bowel disease (IBD). The paper, published in ExRNA, outlines both the pathogenic and therapeutic potential of these molecules.

Professor Xiyang Wei, corresponding author of the study, stated that extracellular vesicles contain RNA molecules that act as messengers for intercellular communication. Wei added that EV-RNAs are core regulators that can be targeted for both diagnosis and treatment.

The Role of EV-RNAs in IBD Pathology

The review integrates findings from multi-omics studies and animal experiments, revealing that EV-RNAs are involved in multiple pathological processes of IBD.

Pathogenic EV-RNAs can trigger inflammatory responses, damage intestinal barriers, and disrupt gut microbiota balance. Conversely, beneficial EV-RNAs can alleviate inflammation and repair damaged intestinal tissue. The research also indicates that gut-derived EV-RNAs may play a role in extraintestinal complications affecting organs like the liver and heart.

Clinical Potential: From Biomarkers to Therapies

Non-Invasive Diagnostics

A major clinical application highlighted is the use of EV-RNAs as non-invasive biomarkers. Specific EV-RNA signatures can distinguish active IBD from remission with reported area under curve values of 0.95-0.97, offering a potential alternative to invasive endoscopic examinations.

Emerging Therapeutic Strategies

Preclinical models show promise for EV-RNA-based treatments. Therapeutic approaches include mesenchymal stem cell-derived EVs, dietary and plant-derived EVs, and engineered EVs.

Challenges to Clinical Translation

Despite the promising outlook, the review identifies key hurdles that must be overcome:

• Standardized protocols for EV isolation, purification, and RNA detection are needed.
• Large-scale clinical trials are required to verify diagnostic and therapeutic efficacy.
• Regulatory pathways for EV-based therapeutics need development.

Background: The Growing Burden of IBD

Inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, is a chronic condition with a rising global prevalence. IBD prevalence is predicted to exceed 1% of the population in early-industrialized regions by 2045. Current diagnosis relies on invasive procedures, and conventional treatments can have systemic side effects or lead to drug resistance, underscoring the need for new approaches.

Publication: The paper "From biomarkers to therapeutics: extracellular vesicle RNA as a pivotal player in inflammatory bowel disease management" was published in ExRNA (DOI: 10.55092/exrna20260003).